Kavar Capital Partners LLC purchased a new stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 3,746 shares of the company’s stock, valued at approximately $35,000.
Several other institutional investors have also recently added to or reduced their stakes in the business. Northern Trust Corp grew its stake in shares of Teva Pharmaceutical Industries by 1.1% during the 1st quarter. Northern Trust Corp now owns 6,763,360 shares of the company’s stock valued at $106,050,000 after acquiring an additional 75,596 shares during the period. Harel Insurance Investments & Financial Services Ltd. grew its stake in shares of Teva Pharmaceutical Industries by 0.5% during the 2nd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 5,348,213 shares of the company’s stock valued at $49,364,000 after acquiring an additional 26,600 shares during the period. Beck Mack & Oliver LLC lifted its holdings in Teva Pharmaceutical Industries by 19.5% in the 1st quarter. Beck Mack & Oliver LLC now owns 4,165,839 shares of the company’s stock worth $65,320,000 after purchasing an additional 678,967 shares in the last quarter. Sumitomo Mitsui Trust Holdings Inc. lifted its holdings in Teva Pharmaceutical Industries by 12.9% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 4,005,074 shares of the company’s stock worth $36,967,000 after purchasing an additional 458,751 shares in the last quarter. Finally, Swiss National Bank lifted its holdings in Teva Pharmaceutical Industries by 1.1% in the 1st quarter. Swiss National Bank now owns 3,571,299 shares of the company’s stock worth $55,998,000 after purchasing an additional 37,200 shares in the last quarter. Institutional investors and hedge funds own 65.28% of the company’s stock.
In related news, VP Notaristefani Carlo De sold 16,070 shares of the stock in a transaction on Monday, May 20th. The stock was sold at an average price of $11.42, for a total transaction of $183,519.40. Following the sale, the vice president now owns 49,659 shares in the company, valued at approximately $567,105.78. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Sol J. Barer purchased 111,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were bought at an average price of $8.98 per share, for a total transaction of $996,780.00. Following the acquisition, the director now directly owns 115,942 shares in the company, valued at approximately $1,041,159.16. The disclosure for this purchase can be found here. 0.49% of the stock is owned by corporate insiders.
A number of research analysts recently commented on TEVA shares. CIBC raised Teva Pharmaceutical Industries from a “market perform” rating to an “outperform” rating and set a $12.00 price target on the stock in a report on Monday, June 3rd. Oppenheimer set a $12.00 price target on Teva Pharmaceutical Industries and gave the stock a “buy” rating in a report on Wednesday, June 12th. Wells Fargo & Co set a $17.00 price target on Teva Pharmaceutical Industries and gave the stock a “hold” rating in a report on Tuesday, May 28th. Morgan Stanley cut Teva Pharmaceutical Industries from an “equal weight” rating to an “underweight” rating and lowered their price target for the stock from $16.00 to $6.00 in a report on Monday, July 15th. Finally, Credit Suisse Group reissued a “neutral” rating on shares of Teva Pharmaceutical Industries in a report on Wednesday, July 10th. Six research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. Teva Pharmaceutical Industries presently has a consensus rating of “Hold” and an average price target of $13.21.
Shares of TEVA traded up $0.25 during mid-day trading on Friday, hitting $6.41. 17,775,000 shares of the stock were exchanged, compared to its average volume of 22,577,100. The company has a market cap of $6.88 billion, a PE ratio of 2.29, a price-to-earnings-growth ratio of 0.65 and a beta of 1.64. Teva Pharmaceutical Industries Ltd has a 52-week low of $6.07 and a 52-week high of $25.96. The firm has a 50-day moving average of $8.14 and a two-hundred day moving average of $12.65. The company has a debt-to-equity ratio of 1.73, a quick ratio of 0.62 and a current ratio of 0.96.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.55 by $0.02. The business had revenue of $4.34 billion for the quarter, compared to analysts’ expectations of $4.25 billion. Teva Pharmaceutical Industries had a positive return on equity of 16.04% and a negative net margin of 21.94%. The company’s revenue for the quarter was down 7.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.78 EPS. On average, sell-side analysts predict that Teva Pharmaceutical Industries Ltd will post 2.25 EPS for the current year.
Teva Pharmaceutical Industries Company Profile
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines and a portfolio of specialty medicines worldwide. It operates through two segments, Generic Medicines and Specialty Medicines. The Generic Medicines segment offers sterile products, hormones, narcotics, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams.
Recommended Story: How do candlesticks reflect price movement?
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.